FBXW7

They also found changes involving MYC, PTEN, PIK3CA, and several other pathways anybody who follows oncology will recognize.

One of the more interesting findings was in feline mammary cancer, where mutations in a gene called FBXW7 showed up in a large percentage of tumors.

Researchers then grew a tiny number of these tumors in three-dimensional models and found that the ones carrying the mutation responded differently to certain chemotherapy drugs.

What interests me is the model itself.

Then we have mutation independent of the indication.

That's the PPP2R1A, FBXW7, cyclin E.

Those patients that have, it can be prostate cancer, it can be breast cancer, it can be other tumor types, but they have to carry this mutation.

The third strategy is specific indication with a specific mutation.